Concerns voiced during January’s U.S. FDA advisory committee meeting failed to deter Cidara Therapeutics Inc. from winning approval by the agency March 22 for once-weekly Rezzayo (rezafungin for injection) to treat a pair of indications – candidemia as well as invasive candidiasis (IC) – in adults with limited or no alternatives.
UT-Battelle LLC has divulged covalent nonstructural protein 3 (nsp3; PLpro) (SARS-CoV) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Current prophylactic and therapeutic approaches for SARS-CoV-2 are effective, but the need for new approaches with broad activity makes virus-host interactions an essential piece to look at.
For COVID-19, the limited durability of vaccines requires multiple injections, and their effectiveness is continuously challenged by emerging new spike variants of the virus. The SARS-CoV-2 main protease Mpro plays a role in major polyprotein processing events and is essential for viral replication.
A Katholieke Universiteit Leuven patent details 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues that act as viral replication inhibitors potentially useful for the treatment of viral infections.
Nucleoside or nucleotide antivirals are a common first-line treatment for viral diseases, acting as direct inhibitors of viral replication and transcription. The nucleoside GS-441524 and its prodrug remdesivir have shown broad-spectrum antiviral activity against several virus families, including Flaviviridae, Filoviridae, Pneumoviridae, paramyxoviruses and Coronaviridae.
Research at Middle Tennessee State University has led to the development of peptoids reported to be useful for the treatment of fungal infections and tuberculosis.
RSS
